Very Long-Term (15 to 20 Years) Clinical and Angiographic Outcome After Coronary Bare Metal Stent Implantation

Background—We previously reported that the long-term luminal response after coronary bare metal stenting is triphasic, with an early restenosis phase spanning the 6 months after the index procedure, an intermediate-term regression phase from 6 months to 3 years, and a late renarrowing phase beyond 4 years. However, the clinical significance of late luminal renarrowing remains unknown. Methods and Results—Angiographic and clinical follow-up of the same cohort of 405 patients with successful Palmaz-Schatz stent placement was extended beyond 15 years. Clinical follow-up was completed in 98% of patients at 5 years and in 81% at 15 years. The incidence of death and cardiac death at 15 years was 45.4% and 20.6%, respectively. Paired long-term (4 to 10 years) and very long-term (>10 years) angiographic studies without intercurrent target lesion revascularization were performed in 55 lesions, and minimal luminal diameter further decreased from 1.88±0.50 mm to 1.60±0.73 mm (P=0.002). Late target lesion revascularization after initial stabilization of the stented segments occurred rarely within 4 years. Beyond 4 years, however, the incidence of late target lesion revascularization increased steadily from 3.3% at 4 years to 24.7% at 15 years. The incidence of definite very late stent thrombosis was low (1.5% at 15 years). Conclusions—Luminal renarrowing of the stented segment beyond 4 years was a progressive process extending beyond 10 years. The angiographic observation of late in-stent restenosis was clinically relevant because a corresponding progressive increase in the incidence of late target lesion revascularization was observed beyond 4 years and up to 15 to 20 years after bare metal stent implantation.

[1]  Antonio Colombo,et al.  5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. , 2010, Journal of the American College of Cardiology.

[2]  A. Colombo,et al.  TAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  J. Marco,et al.  Nine‐year follow‐up of balloon‐expandable Palmaz‐Schatz stent in patients with single‐vessel disease , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[5]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[6]  Renu Virmani,et al.  Healed Plaque Ruptures and Sudden Coronary Death: Evidence That Subclinical Rupture Has a Role in Plaque Progression , 2001, Circulation.

[7]  A. Kirtane,et al.  5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. , 2009, Journal of the American College of Cardiology.

[8]  Y. Hayashi,et al.  Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). , 2010, The American journal of cardiology.

[9]  H Yokoi,et al.  Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.

[10]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[11]  Patrick W Serruys,et al.  Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.

[12]  Renu Virmani,et al.  One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. , 2009, JACC. Cardiovascular imaging.

[13]  P. Serruys,et al.  Long term outcome after coronary stent implantation: a 10 year single centre experience of 1000 patients , 1999, Heart.

[14]  C. Varas‐Lorenzo,et al.  Clinical and sequential angiographic follow-up six months and 10 years after successful percutaneous transluminal coronary angioplasty. , 1999, The American journal of cardiology.

[15]  M. Nobuyoshi,et al.  Long-Term Clinical and Angiographic Follow-Up After Coronary Stent Placement in Native Coronary Arteries , 2002, Circulation.

[16]  M. Nobuyoshi,et al.  Late restenosis of the balloon-dilated site: serial angiographic observations beyond 7 years. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[17]  Hong Wang,et al.  Five-year follow up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial , 2009 .

[18]  M. Nobuyoshi,et al.  Pathological finding of sirolimus-eluting stent (SES) restenosis lesion with black hole appearance on intravascular ultrasound. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[19]  Michio Nakanishi,et al.  Pathological analyses of long-term intracoronary Palmaz-Schatz stenting; Is its efficacy permanent? , 2004, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[20]  Y. Hayashi,et al.  Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation , 2009, Circulation.

[21]  G. Guagliumi,et al.  Long-term (> or =8 years) outcome after Palmaz-Schatz stent implantation. , 2001, The American journal of cardiology.

[22]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.

[23]  John Bresnahan,et al.  Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents , 2007, Circulation.

[24]  Yoshihiko Seino,et al.  Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. , 2009, Journal of the American College of Cardiology.

[25]  E F Cook,et al.  Comparative Reproducibility and Validity of Systems for Assessing Cardiovascular Functional Class: Advantages of a New Specific Activity Scale , 1981, Circulation.